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Abstract: Speech and voice changes are a central feature of the symptom complex of people
with Parkinson’s disease (pwPD). Speaking is a social activity involving the pwPD, family,
and the wider communicative context. Sensory-motor, cognitive-linguistic, and affective
changes in Parkinson’s disease (PD) combine to alter communication, impacting on psycho-
social quality-of-life, leading to risks of social withdrawal and increased depression and
anxiety. The underlying pathophysiology of speech, voice, and communication difficulties in
pwPD is multi-factorial and complex. Sensory-motor changes in the respiratory, phonatory,
and articulatory subsystems, underscaling of effort, and central processing problems are
further affected by broader cognitive-linguistic difficulties, and non-speech motor deficits.
Many studies show that, when pwPD are asked to rate their own voice and how it functions
in everyday situations, they show increased voice-related disability and negative impact
relative to healthy controls. Voice treatment is integral to improving communication in
pwPD. Studies show positive benefits from the perspective of pwPD and carers. Treatment
approaches vary from one-to-one to group interventions, a singular focus on increasing
loudness to more general voice exercises, and choral singing. The nature and underlying
pathophysiology of speech, voice, and communication changes in pwPD are reviewed before
exploring the effects of voice treatment programs and pwPD and carer perceptions of their
effect. Larger scale, better powered, controlled trials of intervention for voice and speech that
measure clinically and socially relevant outcomes are finally underway. Future research
should also focus on issues of treatment compliance, practicality (for service delivery and
use), and long-term follow-up outcomes. The role of carers in longer-term maintenance
represents a further important area of exploration.
Keywords: voice, speech, treatment, quality-of-life, patient perspectives
Introduction
Motor and non-motor changes relating to spoken communication are commonly
experienced by people with Parkinson’s disease (pwPD).1–3 Indeed, changes to
voice quality and loudness frequently represent the first signs for pwPD and their
family that something is amiss.4 Communication ability can be altered by (a) direct
effects from motor changes to respiratory, laryngeal, and articulatory movements,
and (b) cognitive (eg, language processing) and affective consequences (eg, depres-
sion or anxiety). Several other common disruptions to oro-motor functioning,
including dysphagia and sialorrhea, may also exercise secondary effects on speech
and voice.5 (Miller N, Walshe M, Walker R. Sialorrhea in Parkinson's Disease:
Prevalence, impact and management strategies, personal communication, March
2019). Several recent articles have reviewed the nature of speech and language
changes encountered by pwPD.6–8 However, one area of relative neglect concerns
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issues around the effects of communication changes on
daily living as perceived by the pwPD themselves and
their carers. Coupled with this is the issue of how best to
capture these perceptions in clinical treatment planning
and in the evaluation of outcomes, especially important
given the renewed emphasis across recent years to focus
content of intervention and measurement of outcomes on
patient reported and preferred variables. This represents
the focus of this invited review. It aims to provide an
update for speech and language therapists/pathologists,
and other professions involved in supporting pwPD and
their carers on the issue of how communication changes
are viewed by those directly impacted and the clinical
practice consequences of these changes.
The state-of-the-art review first briefly outlines the
scope of communication changes in pwPD and their rela-
tionship to more general underlying pathology before
focusing centrally on the remit of patient and carer perspec-
tives of these changes and treatment programs designed to
address them. Although the title states “voice” treatment,
we interpret that here to encompass all aspects of spoken
communication—respiration, phonation, prosody, and
articulation. For this paper we interpret patient perspectives
regarding voice treatment as meaning one or all of the
following: the use of patient chosen or patient reported
outcome measures (PROMs); documentation of pwPD
reports of the impact of communication difficulties on
everyday living; pwPD views of the process of voice treat-
ment and of speech and language therapy (SLT) interven-
tion in general; and patients’ contributions to the design of
voice treatment. Although the perspectives of pwPD are
a key focus of this paper, we also considered the perspec-
tives of a spouse/carer of a pwPD as integral.
Identification of studies for review entailed a literature
search of Ovid Medline and CINAHL to identify relevant
papers published between 2008 and 2018. Subject head-
ings (MeSH) and text words relating to Parkinson’s dis-
ease (PD), Speech & Language Therapy, voice treatment,
treatment outcomes, patient reported outcomes, and qual-
ity-of-life were used, with the search limited to the English
language. We included studies published between 2008
and 2018 which had voice/speech treatment as a main
focus, which included PROMs and/or sought to obtain
the perspective of pwPD on voice/SLT treatment. The
initial search yielded 75 articles of potential interest. We
excluded papers if: they were not written in English; did
not have voice treatment as the main focus; or did not
include a PROM and/or information pertaining to pwPD
perspectives on voice/SLT treatment. Sixty papers were
excluded on this basis, leaving 16 papers for analysis.
Any additional papers meeting inclusion criteria identified
from reading the selected articles were also included in the
review.
Speech and voice changes in PD
Up to 90% of pwPD report changes to their speech and
voice3,9–11 with around 50% experiencing deterioration
which renders it difficult to make themselves understood
to strangers.9
The underlying pathophysiological bases of voice,
speech, and language changes in PD are complex. Voice
quality changes, reduced loudness, loss of intonation var-
iation, and imprecise articulation relate in part to rigidity
and stiffness in the oral, laryngeal, and respiratory
muscles.12–15 However, stiffness and rigidity are insuffi-
cient to totally account for changes.
A crucial common denominator that appears to link
impairment of articulatory movements, voice production,
hand gestures accompanying speech, as well as many
other non-communication related motor responses, con-
cerns a failure to adequately scale the dynamics of move-
ment to achieve the required range, force, and velocity,
even though basic tone, power, and coordination are suffi-
cient to do so.13,14 Further, pwPD exhibit reduced aware-
ness of the extent and consequences of the under scaling.
This appears associated with a deficit in central sensory
processing.16,17 Thus, the pwPD is able to achieve ade-
quate loudness, articulatory precision and emphasis when
specifically asked to do so—even though increases in
loudness may not match those that unaffected speakers
make when asked to speak loudly.18,19 However, the
pwPD may find it difficult to maintain these features dur-
ing general conversation.
It is also important to emphasize that changes in language
processing affect the speed at which pwPD can formulate and
follow utterances, and can result in some distinct cognitive-
linguistic impairments.11,20–22 Importantly, changes may not
involve just expressive spoken communication but may also
include the understanding and following of the speech of
others. These receptive difficulties apply to prosody too.
PwPD are poorer than people without PD at comprehending
the tone or implications of an utterance that are signaled in
the prosodic content.13,17,23,24 Issues with understanding the
prosodic content of others’ utterances as well as producing
adequate prosodic cues on the part of the pwPD have been
particularly linked to the expression and understanding of
Gillivan-Murphy et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Research and Reviews in Parkinsonism 2019:930
 
R
es
ea
rc
h 
an
d 
Re
vie
ws
 in
 P
ar
kin
so
ni
sm
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
85
.2
11
.2
55
.1
60
 o
n 
21
-J
ul
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
emotional content.14,25,26 Together, the cognitive-linguistic
and prosodic disturbances commonly result in carer reports
that their partner with PD no longer seems to appreciate
humor in the way they used to or regularly misunderstands
conversations where the message relies on decoding proso-
dic, lexical, or syntactic subtleties.
PwPD perspectives on change in
speech and voice
In terms of pwPD perspectives, impaired communication
results in significant restrictions on daily living activities
and social participation, and is strongly associated with
reduced quality-of-life.27–33 Perceived impact can be signif-
icant for the pwPD, even when listeners detect no apparent
major issues with voice and speech.28,30,34–36 PwPD
describe their voice as too quiet, or volume fades fast over
an utterance or in conversation; they describe voice quality
as hoarse, breathy, tremulous, and that they have difficulty
initiating or sustaining utterances.37,38 Freezing of voice can
be as troublesome as freezing of gait.27 Disturbance to
speech prosody (stress, intonation, rhythm of speech) is
also described as a strong feature.39–41 PwPD report the
frustrations of listeners seeming to misunderstand or miss
the emotion they are aiming to convey, or the constant
feeling that people believe them to be depressed, disinter-
ested, and unmotivated when they are not.42–44 Such
impressions are reinforced by hypomimia.45,46 To listeners,
articulation may sound distorted or sounds omitted and/or
syllables and words slurred together, which may give the
impression that the pwPD is speaking too fast. Listeners
also describe sudden rushes of accelerated speech, maybe in
an attempt to complete a sentence on insufficient breath.
Such insights illustrate how challenges in communicat-
ing go well beyond (just) a quiet voice. Furthermore,
difficulty initiating voice often means the pwPD is unable
to signal they want a turn in conversation, with the situa-
tion not aided by a masked expression which removes the
usual facial expression cues one gives to others that one
wishes to say something. Hesitancy and pauses once
a pwPD commences speaking may be mistaken by listen-
ers that a turn was not wanted after all or the pwPD has
finished their contribution. Conversations require sustained
attention with complex switches in topic and between
speakers; they require fast processing of what is said
and, if a reply is to be made, rapid formulation of
a reply. Typically several strands of conversation have to
be attended to simultaneously, and speaking is often
performed alongside other motor activity (eg, walking
and gesturing). Therefore, communication takes place in
a dual or competing task situation and all of these demands
represent areas affected in pwPD.26,47
However, voice and speech convey much more than
merely linguistic messages. They are integral to one’s
view of oneself and how people perceive you. Voice and
speech convey ones personality (eg, warm, distant,
friendly) and how one is feeling (eg, happy, sad, anxious,
tired, excited). Voice and speech also signal ones gender,
age, class, geographical provenance, as well as ones hopes,
allegiances, and aspirations.48 Changes to how all these
are signaled when one has dysphonia, dysarthria, dyspro-
sody, and altered language processing can seriously alter
ones confidence in the view of oneself, and the view that
others might hold of a pwPD. More broadly, people with
acquired motor speech disorders similar to pwPD have
reported these changes as a kind of personality
theft.49,50They feel unable to convey the deeper message
they intend, and feel that listeners continually misinterpret
the sentiments, emotions, beliefs, and affective intentions
they wish to convey. Loss of the ability to communicate in
the way they used to, the way they wish to, may lead to
a sense of bereavement as much as losing a limb, eyesight,
or a friend.51
These factors translate into common threads in reports
from pwPD about how communication changes impact on
them and their families. In a questionnaire survey,10,30
pwPD rated themselves (compared with before they had
PD) as less in control in conversations, that communica-
tion was more frustrating, that it was harder to get the
message across, and that they felt less confident, less
adequate, and less independent. Interviews with
pwPD27,33 disclose concerns over the effort (and conse-
quent added fatigue) involved in communicating, chal-
lenges from the vigilant attention required, and from the
physical challenge of sustaining intelligible speech.
Speakers felt they had to make decisions between not
always joining in conversations in order to conserve
energy but at the same time not wishing to withdraw
from social discourse altogether. Frustrations arose too
from people talking across them, not permitting enough
time for responses, having to repeat over and again, and
from being perceived as muddled or stupid. In addition to
coping with the impairment arising from communication
changes, pwPD also have to cope with issues of loss of
confidence, social withdrawal, and change in
personality.27,30,33,50
Dovepress Gillivan-Murphy et al
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Such reports are consistent with the growing emphasis
on patient-centered care and the shift from a narrow focus
purely on speech-voice mechanics.52 People experience
dysarthria differently, and personal context (including co-
existing physical disability) is important in deciding the
nature (and delivery) of treatment.28,50,53,54 Yorkston et al55
identify five important themes to consider in treatment for
pwPD: (1) the difficulty of thinking about how to speak as
well as what to say (thinking about speaking); (2) fatigue
related to trying to “make the unconscious conscious”
(weighing value vs effort); (3) expressions of frustration,
embarrassment, and loss (feelings about speaking); (4) the
distracting effect of PD on the other person (people and
places); (5) waiting until medication takes effect to talk
(PD and speaking). Spurgeon et al56 describe four further
considerations: (1) emotional reactions (eg, frustration,
embarrassment, lack of confidence, anxiety); (2) physical
impact (eg, fatigue, breathing, and swallowing); (3) prac-
tical aspects (eg, cost of treatment, waiting times), and (4)
expectations about treatment (met vs unmet expectations).
These points offer a number of important implications
for assessment and intervention, as discussed in the next
section.
Assessment considerations
Traditional assessment of PD speech characteristics concen-
trate on assessing speech/voice loudness (habitual loudness
and variability of loudness), voice quality, articulatory pre-
cision, prosody, and intelligibility.54,57,58 However, the
patient and carer experience require detailed assessment
too, in particular for how communication changes impact
on daily living and psychosocial well-being. Increasingly
attention to this aspect of outcomes is attended to through
use of patient reported outcome measures (PROMs).
Studies summarized in Table 1 show that PROMs are
utilized to some extent in treatment studies using the
LSVT® programme56,59–62 variants of LSVT,63–65 and
programs based on singing and group voice treatment.65–68
The measures are widely used in voice clinics, and include
the Voice Handicap Index (VHI),69 the Voice Activity &
Participation Profile (VAPP),70 and the Voice Related
Quality of Life Measure (V-RQoL).71 PROMs, in addition
to measuring disability, allow the clinician to measure the
effect of intervention on a person’s quality-of-life regarding
activity and participation in social situations. Several such
tools specifically devised for pwPD/dysarthria have been
developed and psychometrically validated, including the use
of semantic differential scales,30 the Dysarthria Impact
Profile (DIP),53 the Communicative Effectiveness Survey
(CES),72 and the Communicative Participation Item Bank
(CPIB).73 Some studies have used questionnaires and/or
interviews to find out from pwPD and spouse/carer what
are the issues related to communication for them in daily
living.2,33,56,65 Together the PROMs designed to measure
disability related to voice/speech difficulties and first hand
reports from pwPD and spouse/carer point to issues that
should be addressed in treatment. These issues will be
elaborated on in a later section, titled “PwPD perspectives
regarding speaking and voice treatment”.
Treatment outcomes relating to
PROMs and patient perspectives
Intervention that focuses on improving loudness, articula-
tory precision, and unambiguous prosodic signals is a first
step in rehabilitation. However, communication is social
and, hence, rehabilitation must also address how to employ
improvements to gain entry to and maintain an individual’s
part in conversations. Further, as problems maintaining
intelligibility increase in dual- or competing task contexts,
intervention should employ methods that tackle mainte-
nance and generalization of communicative competence
outside the clinic room in naturalistic environments that
are inherently of a dual and competitive task nature. The
treatment studies summarized in Table 1 highlight that
different approaches (eg, LOUD®, LSVT variations, stan-
dard SLT treatment, voice/singing) and different treatment
contexts (one-to one, group, online) have been used.
Considering the salience and functional impact of loud-
ness deficits in pwPD, it is not surprising that a major
treatment focus has been on increasing loudness levels
(also measured sometimes as sound pressure level, SPL)
in an effort to improve overall intelligibility. The Lee
Silverman Voice Treatment (LSVT®) approach developed
pre-existing attention to effort techniques to specifically
address this.62 The main outcome measures are SPL when
producing a prolonged /a/, and intelligibility rating of
a reading passage and conversational speech. In addition,
the LSVT® program evaluates the perception of the
spouse/carer regarding a range of parameters, including
loudness, intelligibility of speech, initiating conversation,
using a 100 m visual analog scale (VAS).
The effect of treatment on voice disability, communi-
cative function, and social interaction and the duration of
any treatment benefit is highly relevant. Table 1 sum-
marizes the findings of treatment studies (2008–2018)
Gillivan-Murphy et al Dovepress
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which incorporated a patient reported outcome measure
(PROM) and/or sought to determine the perspective of
pwPD of speech/voice and/or treatment. A range of
PROMs including the VHI,59–61,65–67,74 the V-RQOL,74
VAPP,64 LSVT VAS,59,60 and CETI- M59,62 for spouse/
carers were used to determine the effects of treatment.
The studies reviewed show a mixed picture regarding
voice treatment effect on disability both in the immediate
post-treatment and longer term period. Using the VHI in
an 8 -week voice group “mimicking” LSVT, Searl et al65
reported a statistically significant reduction in VHI scores
in the immediate post-treatment period whereas Elefant
et al,66 in a 20 -week music therapy group, reported
a slight increase (increasing disability) without signifi-
cance post-treatment. Studies have also looked at the
longer-term effects of intervention using the VHI.59–61,67
Moya-Galé et al,61 using LSVT®, reported a reduction in
scores without significance 1 month post-treatment. Shih
et al67 reported a slight non-significant increase in scores
(increased disability) 3 months post-treatment using group
choral singing. Halpern et al,59 using LSVT® with assisted
technology, reported a reduction in VHI scores without
statistical significance 6 months post-treatment. Finally,
in a retrospective clinical audit of pwPD receiving
LSVT®, Wight andMiller60 reported a significant reduc-
tion (improvement) in VHI scores at 12 months, which
was not maintained at 24 months.
Using different PROMs measures to the VHI, other
studies also show mixed findings regarding the effect of
treatment on voice disability and communication. Shih
et al67 found no significant change in VRQoL scores in
the immediate or 3-months post-treatment period when
pwPD engaged in a group singing therapy. Simberg et al64
reported a reduction in VAPP scores (improvement) fol-
lowing an intensive 15 day rehabilitation course in
speech and voice treatment 6 months and 12 months post-
treatment without significance. Finally, using the CETI-
M, which is a broader communicative measure than any
of the aforementioned voice disability measures, Ramig
et al,62 using LSVT® in an RCT, reported a significant
change in median CETI-M scores at 1 and 7 months post-
treatment.
To take a broader look at the level of evidence for
voice treatment studies covered by this review, we also
applied the Oxford Centre of Evidence-Based Medicine
2011 Levels of Evidence table,75 which ranges from level
1 (systematic review of randomized trials) to level 5
(mechanism-based reasoning studies). Table 1 shows that
the majority of intervention studies (n=8) were prospective
non-randomized controlled cohort studies (Level 3), but
with two RCT studies (Level 2). Clearly a larger range of
high quality (Level 2) intervention studies would
strengthen the evidence base.
Improved social participation is an important indicator
of treatment outcomes, since it shows that intervention has
made a meaningful impact on the ability of a pwPD to do
the things he/she wants and needs to do.53,72,73 The World
Health Organization, International Classification of
Functioning, Disability and Health (ICF)76 defines partici-
pation as “involvement in life situations”. The
Communicative Participation Item Bank (CPIB)77 was
designed as a self-report measure, intended for community
dwelling adults across a range of communication disorders
and life situations specifically to measure communicative
participation. Used in a large cohort of 378 pwPD in the
US and New Zealand, the CPIB results (alongside other
PD specific, a Global Health Instrument, and self-report
measures) showed that communicative participation in
pwPD is influenced by demographic and disease-based
variables.73 The findings call for a broader view of the
communicative experiences of pwPD. Increased use of the
CPIB, DIP, and similar tools in future PD treatment studies
would enhance the knowledge of pwPD communicative
participation in everyday life and how it changes in
response to SLT and/or voice intervention.
PwPD perspectives regarding
speaking and voice treatment
Consistent with the growing emphasis on patient-cent
ered care,52 we need to understand the issues for
a pwPD communicating on a day-to-day basis and to
hear their experience of living with a communication
disability, their experience of voice treatment, and what
they would like to see happen in the future. Important
contributions emerge when patients and spouses are
asked directly to give their opinions through interviews
and surveys.55,56 When the views of 24 community
dwelling pwPD were sought regarding their communica-
tion experiences, five subthemes emerged including:
difficult to think about how to speak as well as what
to say (thinking about speaking); fatigue related to try-
ing to make the unconscious conscious (weighing value
vs effort); expressions of frustration, embarrassment,
and loss (feelings about speaking); the distracting effect
of PD on the other person (people and places); waiting
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until the PD pills take effect to talk (PD and
speaking).55
Regarding voice treatment and/or SLT, pwPD have
reported positive comments in studies.54,56,64 However,
since the focus of the above studies was to identify areas
of potential improvement (rather than what SLT interven-
tion is working well for pwPD), there is little elaboration
in the studies regarding what pwPD and or carers found
helpful. PwPD commonly report the importance of peer
support (meeting others with PD) during
treatment.54,64,67,78 For example, the participants in
Simberg et al’s64 15-day treatment study emphasized the
positive effect of peer support during the course which had
combined one-to-one and group therapy. This is highly
relevant feedback since the LSVT LOUD treatment
approach delivered in a one-to-one context (face-to-face
or remotely) is used more frequently than any other voice
treatment approach for pwPD in many countries.
Stegemoller et al78 reported findings from an 8 -week
group program delivered by a music therapist to 20
pwPD, with a focus on voice exercises and singing.
PwPD found the group fun, enjoyed the social aspect of
meeting others with PD, and valued an outlet independent
of family members and close friends.
Studies that have focussed specifically on pwPD per-
spectives provide valuable insight into the issues for pwPD
embarking on a rehabilitation journey, and how SLT inter-
vention could address these concerns.2,33,54–56 Using
a survey approach, Miller et al2 reported on 168 pwPD
and 47 carers views regarding SLT service provision relat-
ing to communication and swallowing. Their goal was to
ascertain the issues that were a priority for attention for
pwPD (those who had received an SLT referral, and those
who had not), the methods of delivery and organization,
and the level of support that might be favored. Pointers for
improvement centered on the timing, intensity, duration,
and access to SLT, as well as issues around transfer and
maintenance of gains outside the clinic and (lack of)
attention to psychosocial dimensions. Availability of
ongoing support as the situation evolved and access to
SLT when it was needed were two prominent features in
pwPD feedback.
Other studies report negative issues which could
impact adversely on rehabilitation outcomes. Spurgeon
et al,56 in a qualitative telephone interview pilot study of
nine pwPD who had received voice treatment (NHS stan-
dard treatment or LSVT), found that emotional factors
associated with having speech/voice problems and
treatment were the biggest issue for the interviewees.56
The pwPD talked about the persistence of speech problems
after treatment (the embarrassment, lack of confidence,
disappointment, and anxiety related to their communica-
tion difficulties), and fatigue related to getting to and from
sessions. On a practical level, issues related to the cost of
treatment, waiting list times, and the actual clinical experi-
ence were also raised by pwPD during the interviews.
A final issue emerged relating to met vs unmet expecta-
tions around therapy outcomes and maintenance of therapy
over time. PwPD with high expectations from therapy
were typically disappointed with the clinical outcomes
and maintenance over time, in contrast to those with
lower expectations, who gave more positive feedback on
the process and the results.56
These aforementioned studies provide important
insight into the perspectives of pwPD regarding their
lived experiences with a communication disability and
their views on voice treatment. Another and often forgot-
ten aspect is finding out from the pwPD spouse and/or
caregiver their views on the impact of the communication
disability on their relationship and social.
The spouse/carer perspective
Communication changes occur in a social context.
Consequently, it is important to explore the views of
the spouse/carer of a pwPD views concerning the com-
munication difficulty, the impact on everyday living,
social interaction, and emotional well-being, and the
value of the treatment approaches. In Miller et al’s2
study, carers reported a number of issues in relation to
their specific pwPD including “reduced loudness” (25%),
a reluctance to engage in conversations (21%), social
isolation (23%), and a reduction in confidence.
Whitehead33 interviewed three spouses of pwPD in
a qualitative interview based study. The spouses consid-
ered that, for their respective pwPD, communication was
limited because of a number of factors including speech
& language changes, loss of confidence, and social with-
drawal. These carer observations are clearly similar to the
pwPD self-reports.
A number of carer’s questionnaires,59,60,64 interviews,64
and surveys30,54 have been used to as a voice treatment
outcome measure. Wight and Miller60 in their LSVT treat-
ment study showed that spouse/carers rated all areas on the
LSVT VAS as having improved significantly post-therapy.
However, at 12 months, only perceived loudness, strain,
mumbling, and intelligibility remained statistically
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significantly above baseline with no significant gains per-
sisting to 24 months. Halpern et al59 used the CETI-M and
the LSVT VAS with carers. The CETI-M asks significant
others to indicate how effective they believe that the parti-
cipant is at communicating in each of 10 different situa-
tions. Simberg et al,64 in their interviewing of six spouses of
pwPD post in-patient intensive treatment, focused on loud
voicing and intonation, reported that all spouses had noticed
a change in the voices of the respective pwPD, with voice
being more vivid and expressive, easier to understand, and
with no need for repeating utterance as before. These
changes remained relatively constant 3 months after the
first part of the course, when all the spouses were inter-
viewed by telephone.
In conclusion it would seem that the carer’s perspective
of the impact of voice and speech therapy treatment pro-
vides valuable information, but is currently limited and
worthy of significantly more investigation.
Conclusion
This review has highlighted that the motor changes of
PD may influence voice and speech, but there are
additional issues related to the disease process itself,
including fatigue, cognitive decline, and medication
effects that together impact on social functioning, and
emotional well-being for the pwPD and his/her spouse.
This review shows that voice treatment studies
(2008–2018) are primarily impairment focused, with
PROMs used to measure disability pre- and post-
treatment. Alongside this, some studies extend voice treat-
ment into singing and group voice work, as an adjunct to
traditional one-to-therapy, or as a sole treatment approach.
A number of voice and speech therapy treatment
programs show promise at improving speech and voice
parameters as well as quality-of-life. In general terms,
pwPD appear positive about SLT and/or voice
treatment.54–56,62,64,65,78 However, it seems as though
emotional factors and long-term maintenance issues are
rarely addressed in current treatment programs.54,56
Similarly, practical issues such as fatigue related to
traveling to sessions, treatment cost, and waiting list
times are rarely considered.54,56
Moving forward, greater cognisance should be given to
the lived experiences of pwPD (and their spouses) with
a communication disability, and how SLT/voice treatment
can best support the patient. Issues for consideration are
optimum location for treatment (transport issues), timing
(medication-related), frequency and duration of treatment
(fatigue), one-to-one and/or group treatment, etc.
Future research should also focus on treatment compli-
ance, practicality, and long-term follow-up. It is acknowl-
edged the carer of the pwPD is a key partner, especially for
wider implementation and maintenance of gains and jud-
ging intervention efficacy.
Abbreviation list
CES, Communicative Effectiveness Survey; CETI-M,
Modified Communication Effectiveness Index; CPIB,
Communicative Participation Item Bank; GSI, Group
Singing Intervention; HC, healthy controls; LSVT-X,
LSVT extended; MPT, maximum phonation time; MEP,
maximum expiratory pressure; MIP, maximum inspiratory
pressure; NHS, National Health Service; N/A, not applic-
able; UNTXPD, Untreated PD; SPL, sound pressure level;
VAPP, voice activity and participation profile; VAS, Visual
Analog Scale; VHI, Voice Handicap Index; V-RQoL, voice
related quality-of-life measure.
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